Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study

ConclusioniGlarLixi administration resulted in early absorption of both iGlar and lixisenatide with a good tolerability profile in healthy Chinese participants. These results are consistent with the previously published data from other geographic regions.Trial registrationU1111-1194-9411.

http://rd.springer.com/10.1007/s13300-023-01434-0

Source: Diabetes Therapy - June 17, 2023 Category: Endocrinology Source Type: research